A Bayesian approach to bioequivalence for the 2 x 2 changeover design

Area of Science:

• Pharmacokinetics and Biopharmaceutics
• Statistical Methods in Drug Development
• Bayesian Statistics

Background:

• Bioequivalence trials compare drug formulations with the same active ingredient to ensure similar plasma concentration-time profiles.
• The 2x2 crossover design is commonly used, comparing a test formulation against a standard.
• Traditional methods may lack flexibility in handling complex trial aspects like carry-over effects.

Purpose of the Study:

• To propose a Bayesian criterion for bioequivalence based on posterior probability.
• To evaluate the sensitivity of this criterion to different prior assumptions.
• To incorporate carry-over effects within a Bayesian framework for bioequivalence assessment.

Main Methods:

• Utilizing a Bayesian statistical framework for bioequivalence analysis.
• Developing a criterion based on the posterior probability of the difference in formulation means relative to the standard mean.
• Investigating the impact of alternative prior distributions on the posterior probability.
• Incorporating carry-over effects directly into the Bayesian model.

Main Results:

• A novel Bayesian criterion for bioequivalence is proposed, focusing on the posterior probability of mean differences.
• The sensitivity analysis demonstrates the influence of prior choices on the bioequivalence assessment.
• The Bayesian approach effectively accommodates carry-over effects without preliminary testing.

Conclusions:

• The proposed Bayesian method offers a robust and flexible approach to bioequivalence trials.
• This framework allows for a more nuanced assessment of formulation comparability, especially when considering carry-over effects.
• The study highlights the advantages of Bayesian statistics in drug development and pharmacokinetic analysis.